International Clinical Trial: Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07115667) titled 'Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration' on Aug. 3.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Condition: Solitary Bone Plasmacytoma Plasmacytoma of Bone Plasma Cell Disorders

Intervention: Drug: BCMA/CD3 bispecific antibody (CM336)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 10, 2025

Target Sa...